Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
1.015
-0.155 (-13.25%)
At close: Aug 14, 2026, 4:00 PM EDT
1.010
-0.005 (-0.49%)
After-hours: Aug 14, 2026, 7:51 PM EDT
Tempest Therapeutics Employees
Tempest Therapeutics had 5 employees as of March 31, 2026. The number of employees increased by 1 or 25.00% since the number was last reported on December 31, 2025.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$8,094,400
Market Cap
16.22M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 5 | 1 | 25.00% |
| Dec 31, 2025 | 4 | -20 | -83.33% |
| Dec 31, 2024 | 24 | 7 | 41.18% |
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 115 |
| Citius Pharmaceuticals | 23 |
| Werewolf Therapeutics | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| KALA BIO | 6 |
| Marker Therapeutics | 5 |
TPST News
- 1 day ago - Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 1 day ago - Tempest Therapeutics Earnings release: Q2 2026 - Filings
- 1 day ago - Tempest Therapeutics Quarterly report: Q2 2026 - Filings
- 17 days ago - Tempest Therapeutics Proxy statement: Proxy filing - Filings
- 24 days ago - Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T - GlobeNewsWire
- 4 weeks ago - Tempest Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Tempest Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 - GlobeNewsWire